Compare GCTS & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCTS | LONA |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | 126 | 19 |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.5M | 90.4M |
| IPO Year | N/A | N/A |
| Metric | GCTS | LONA |
|---|---|---|
| Price | $3.38 | $10.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 7.5M | 32.5K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,052.30 | N/A |
| Revenue Next Year | $140.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $4.21 |
| 52 Week High | $3.57 | $14.21 |
| Indicator | GCTS | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 81.08 | 57.58 |
| Support Level | $1.24 | $7.88 |
| Resistance Level | N/A | $11.96 |
| Average True Range (ATR) | 0.40 | 1.03 |
| MACD | 0.19 | -0.00 |
| Stochastic Oscillator | 89.78 | 67.76 |
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness. Geographically, operates in South Korea and the United States, with maximum revenue from the USA.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.